12/14/21 6:48 AMNasdaq : NRXP covid-19NRx Pharmaceuticals Announces New, Favorable Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19After Review of More than 348 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Identified by Independent Data Safety Monitoring Board; Study Cleared to Continue Enrollment to Target 640 Patients First Patient in Brazil Expected to be Included in US National Institutes ofRHEA-AInegative
12/09/21 9:21 AMNasdaq : NRXP covid-19NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI® and BriLife COVID-19 Vaccine TrialsNRx Pharmaceuticals (NASDAQ: NRXP ) today announced the conclusion ofRHEA-AIneutral
12/06/21 9:07 AMNasdaq : NRXP clinical trialNRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia, Israel, European Union, and Other RegionsIndependent Data Safety Monitoring Board has completed review of BriLife phase 2 trial at low, medium, and high doses, with a formal report expected imminently NRx has obtained advice from European Medicines Authority and World Health Organization on phase 2b/3 registration trial protocol More thanRHEA-AIneutral
11/29/21 6:31 AMNasdaq : NRXP covid-19NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population Analysis was conducted in response to US Food and Drug Administration (FDA) request forRHEA-AIneutral
11/26/21 10:06 AMNasdaq : NRXP covid-19NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological ResearchAnalysis of Blood Samples from Patients who Responded to the BriLife ® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original “Wild-Type” Virus Data Suggest that the BriLife Vaccine May Be Capable of Evolving to Counter DeltaRHEA-AInegative
11/16/21 5:56 AMNasdaq : NRXP earningsNRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial ResultsNRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, atRHEA-AIneutral
11/12/21 11:46 AMNasdaq : NRXP conferencesNRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel ConferenceNRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Jonathan Javitt, will be presenting updates to theRHEA-AIneutral
11/11/21 7:54 AMNasdaq : NRXP NRx Pharmaceuticals Receives US Food and Drug Administration Review of ZYESAMI® (aviptadil) Manufacturing InformationNRx Pharmaceuticals (NASDAQ: NRXP ), today announced receipt of the US Food and DrugRHEA-AIpositive
11/09/21 12:32 PMNasdaq : NRXP conferencesNRx Pharmaceuticals to Report Third Quarter 2021 Financial and Business Update on Tuesday, November 16, 2021NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical-stage, global biopharmaceutical company, today announced that management will report third-quarter 2021 financialRHEA-AIneutral
11/05/21 6:48 AMNasdaq : NRXP covid-19NRx Pharmaceuticals Initiates Senior Level Finance and Business Initiatives with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife® COVID-19 Vaccine ProductionNRx Pharmaceuticals (NASDAQ: NRXP), via its subsidiary, NRx Luxembourg (NRx), has concluded a business mission to Luxembourg at the invitation of the Luxembourg Ministry of the Economy in preparation for the establishment of vaccine manufacturing capabilityRHEA-AIvery positive